Company Oxurion NV

Equities

OXUR

BE0003846632

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 09:18:50 2024-04-24 am EDT			5-day change	1st Jan Change
0.0001 ^EUR	0.00%		0.00%	-88.89%

Apr. 12	Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 06	Oxurion Raises Additional Funds from Convertible Bonds Issue	MT

Oxurion NV is a biopharmaceutical company developing next generation therapies, designed to improve and better preserve vision in patients with retinal disorders including Geographic Atrophy (GA), the leading cause of vision loss in elderly people worldwide.

Oxurion NV is aiming to build the leading global franchise in the treatment of Age-related macular degeneration (AMD), based on the successful clinical development of its two novel therapeutics: THR-149, a plasma kallikr

ein inhibitor being developed as a potential new standard of care for AMD patients who respond sub-optimally to anti-VEGF therapy, and THR-687, a pan-RGD integrin inhibitor, initially being developed as a potential new standard of care for all AMD patients.

Number of employees: 20

EUR in Million	2022	Weight	2023	Weight	Delta
Vials 58.6 %	0	74.3 %	0	58.6 %	-65.16%
Royalties 41.4 %	0	25.7 %	0	41.4 %	-28.76%

EUR in Million	2022	Weight	2023	Weight	Delta
Belgium 100.0 %	1	100.0 %	0	100.0 %	-55.80%

Managers	Title	Age	Since
Ghoson Pascal CEO	Chief Executive Officer	-	Dec. 27
Andy de Deene PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Anat Loewenstein BRD	Director/Board Member	64	23-05-01
James Hartmann BRD	Director/Board Member	58	Dec. 27
Nathalie Laarakker BRD	Director/Board Member	-	23-05-01
Ghoson Pascal CEO	Chief Executive Officer	-	Dec. 27

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	9,014,821,287	8,120,878,388 ( 90.08 %)	0	90.08 %

Name	Equities	%	Valuation
Global Opportunities (GO) Capital Asset Management BV 0.0130 %	958,444	0.0130 %	211 €
CAPFI DELEN Asset Management NV 0.002559 %	189,000	0.002559 %	42 €
Delta Lloyd Asset Management NV 0.001512 %	111,616	0.001512 %	25 €
FundQuest Advisor 0.001355 %	100,051	0.001355 %	22 €
EValuation Capital Management BV 0.000948 %	70,000	0.000948 %	15 €
Inversis Gestión SGIIC SA 0.000937 %	69,157	0.000937 %	15 €
Skylar France SASU 0.000813 %	60,000	0.000813 %	13 €
Deminor Investment Management BV 0.000786 %	58,057	0.000786 %	13 €
Cominvest Asset Management GmbH 0.000785 %	58,000	0.000785 %	13 €
ABN AMRO Bank NV (Belgium) 0.000664 %	49,029	0.000664 %	11 €

Oxurion NV

Gaston Geenslaan 1 Heverlee

3001, Leuven

+32 1 675 13 10

http://www.oxurion.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
OXURION NV	-88.89%	616K
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research